vs

Side-by-side financial comparison of IMMUCELL CORP (ICCC) and MESABI TRUST (MSB). Click either name above to swap in a different company.

IMMUCELL CORP is the larger business by last-quarter revenue ($5.5M vs $3.6M, roughly 1.5× MESABI TRUST). MESABI TRUST runs the higher net margin — 77.1% vs -2.5%, a 79.6% gap on every dollar of revenue. On growth, IMMUCELL CORP posted the faster year-over-year revenue change (-8.4% vs -95.5%). Over the past eight quarters, IMMUCELL CORP's revenue compounded faster (3.9% CAGR vs -24.1%).

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

Mesabi Trust is a United States-based royalty trust that holds permanent royalty interests in iron ore mining properties located in Minnesota's Mesabi Range. It earns revenue primarily from royalty payments tied to the production and sale of iron ore products, with core earnings sourced from active mining partners operating on the land it holds interests in, catering to the global steel manufacturing market.

ICCC vs MSB — Head-to-Head

Bigger by revenue
ICCC
ICCC
1.5× larger
ICCC
$5.5M
$3.6M
MSB
Growing faster (revenue YoY)
ICCC
ICCC
+87.0% gap
ICCC
-8.4%
-95.5%
MSB
Higher net margin
MSB
MSB
79.6% more per $
MSB
77.1%
-2.5%
ICCC
Faster 2-yr revenue CAGR
ICCC
ICCC
Annualised
ICCC
3.9%
-24.1%
MSB

Income Statement — Q3 FY2025 vs Q3 FY2026

Metric
ICCC
ICCC
MSB
MSB
Revenue
$5.5M
$3.6M
Net Profit
$-139.7K
$2.8M
Gross Margin
42.9%
77.1%
Operating Margin
0.4%
Net Margin
-2.5%
77.1%
Revenue YoY
-8.4%
-95.5%
Net Profit YoY
80.1%
-96.5%
EPS (diluted)
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ICCC
ICCC
MSB
MSB
Q4 25
$3.6M
Q3 25
$5.5M
$5.6M
Q2 25
$6.4M
$4.7M
Q1 25
$8.1M
$6.9M
Q4 24
$7.8M
$79.0M
Q3 24
$6.0M
$6.5M
Q2 24
$5.5M
$6.3M
Q1 24
$7.3M
$6.2M
Net Profit
ICCC
ICCC
MSB
MSB
Q4 25
$2.8M
Q3 25
$-139.7K
$4.7M
Q2 25
$501.9K
$3.6M
Q1 25
$1.4M
$6.1M
Q4 24
$78.3M
Q3 24
$-701.7K
$5.4M
Q2 24
$-1.5M
$3.5M
Q1 24
$-437.9K
$4.7M
Gross Margin
ICCC
ICCC
MSB
MSB
Q4 25
77.1%
Q3 25
42.9%
84.6%
Q2 25
43.7%
76.7%
Q1 25
41.6%
88.5%
Q4 24
36.5%
99.1%
Q3 24
26.3%
83.2%
Q2 24
22.5%
55.7%
Q1 24
31.6%
75.3%
Operating Margin
ICCC
ICCC
MSB
MSB
Q4 25
Q3 25
0.4%
Q2 25
8.8%
Q1 25
13.9%
Q4 24
8.0%
Q3 24
-9.6%
Q2 24
-25.3%
Q1 24
-4.1%
Net Margin
ICCC
ICCC
MSB
MSB
Q4 25
77.1%
Q3 25
-2.5%
84.6%
Q2 25
7.8%
76.7%
Q1 25
17.9%
88.5%
Q4 24
99.1%
Q3 24
-11.7%
83.2%
Q2 24
-28.0%
55.7%
Q1 24
-6.0%
75.3%
EPS (diluted)
ICCC
ICCC
MSB
MSB
Q4 25
Q3 25
$-0.02
Q2 25
$0.06
Q1 25
$0.16
Q4 24
$0.09
Q3 24
$-0.09
Q2 24
$-0.20
Q1 24
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ICCC
ICCC
MSB
MSB
Cash + ST InvestmentsLiquidity on hand
$3.9M
Total DebtLower is stronger
$9.5M
Stockholders' EquityBook value
$29.8M
$21.1M
Total Assets
$45.7M
$26.0M
Debt / EquityLower = less leverage
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ICCC
ICCC
MSB
MSB
Q4 25
Q3 25
$3.9M
Q2 25
Q1 25
Q4 24
$3.8M
Q3 24
Q2 24
$1.3M
Q1 24
$960.3K
Total Debt
ICCC
ICCC
MSB
MSB
Q4 25
Q3 25
$9.5M
Q2 25
Q1 25
$8.7M
Q4 24
$9.0M
Q3 24
$9.4M
Q2 24
$9.8M
Q1 24
$10.2M
Stockholders' Equity
ICCC
ICCC
MSB
MSB
Q4 25
$21.1M
Q3 25
$29.8M
$22.8M
Q2 25
$29.9M
$19.6M
Q1 25
$29.0M
$23.3M
Q4 24
$27.5M
$95.3M
Q3 24
$26.4M
$22.1M
Q2 24
$23.5M
$20.7M
Q1 24
$24.6M
$21.0M
Total Assets
ICCC
ICCC
MSB
MSB
Q4 25
$26.0M
Q3 25
$45.7M
$24.8M
Q2 25
$46.7M
$27.4M
Q1 25
$45.6M
$101.7M
Q4 24
$45.1M
$100.7M
Q3 24
$44.4M
$26.2M
Q2 24
$41.9M
$25.1M
Q1 24
$43.1M
$26.7M
Debt / Equity
ICCC
ICCC
MSB
MSB
Q4 25
Q3 25
0.32×
Q2 25
Q1 25
0.30×
Q4 24
0.33×
Q3 24
0.36×
Q2 24
0.42×
Q1 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ICCC
ICCC
MSB
MSB
Operating Cash FlowLast quarter
$-1.2M
$3.5M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-32.3%
Capex IntensityCapex / Revenue
10.8%
Cash ConversionOCF / Net Profit
1.27×
TTM Free Cash FlowTrailing 4 quarters
$715.4K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ICCC
ICCC
MSB
MSB
Q4 25
$3.5M
Q3 25
$-1.2M
$4.4M
Q2 25
$1.6M
$2.1M
Q1 25
$1.6M
$93.9M
Q4 24
$-3.1K
$78.2M
Q3 24
$-639.3K
$3.8M
Q2 24
$581.8K
$2.5M
Q1 24
$418.5K
$14.6M
Free Cash Flow
ICCC
ICCC
MSB
MSB
Q4 25
Q3 25
$-1.8M
Q2 25
$1.4M
Q1 25
$1.2M
Q4 24
$-199.3K
Q3 24
$-727.7K
Q2 24
$471.0K
Q1 24
$348.1K
FCF Margin
ICCC
ICCC
MSB
MSB
Q4 25
Q3 25
-32.3%
Q2 25
22.4%
Q1 25
15.4%
Q4 24
-2.6%
Q3 24
-12.1%
Q2 24
8.6%
Q1 24
4.8%
Capex Intensity
ICCC
ICCC
MSB
MSB
Q4 25
Q3 25
10.8%
Q2 25
2.4%
Q1 25
4.1%
Q4 24
2.5%
Q3 24
1.5%
Q2 24
2.0%
Q1 24
1.0%
Cash Conversion
ICCC
ICCC
MSB
MSB
Q4 25
1.27×
Q3 25
0.92×
Q2 25
3.19×
0.57×
Q1 25
1.09×
15.48×
Q4 24
1.00×
Q3 24
0.71×
Q2 24
0.72×
Q1 24
3.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons